The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…

Johnson & Johnson

J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline

Xtandi, cornerstone of Pfizer's $14B Medivation buy, falls short in closely watched study

Would Sanofi overpay for Actelion? If it pays a rumored $30B, then yes, analysts say

Payers may see biosims as a no-brainer, but marketing them won't be

Sanofi weighs Actelion offer to compete with J&J's $27B: Bloomberg

Who wants to be a billionaire? Not Actelion’s founder and CEO, if it means selling out

Astellas scouts pipeline buys for post-Xtandi future

Takeover-hungry J&J hikes its Actelion bid past $26B

FT: Actelion's not down for an outright J&J buy. But something more complex? Maybe